New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases

  • Pivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIs
  • ELARA results for Kymriah® in relapsed or refractory (r/r) follicular lymphoma, plus long-term JULIET data on response survival and durability at more than three years in r/r DLBCL patients
  • Detailed Jakavi …
/by

Achieving 100% renewable electricity

Photovoltaic power plant in Egypt - Photo credit / copyright: ACCIONA

Novartis signed five virtual power purchase agreements (VPPAs), which are expected to collectively add 277 megawatts of clean power to the electrical grid. This move makes Novartis the first pharmaceutical company set to achieve …

/by

Novartis set to achieve 100% renewable electricity in its European operations

  • Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical grid

  • Projects expected to address Novartis greenhouse gas emissions across its European operations, equivalent to removing approximately 113 000 passenger vehicles from the road annually1

  • Agreements mark a major milestone on the Novartis environmental sustainability journey to be carbon neutral …
/by

Making Possible: Stepping toward a future with cell and gene therapy

Novartis scientist Leila Haery likes to step away from the lab and wander in nature for perspective. While outdoors, the gene therapy expert contemplates the vastness of landscapes and their evolution over time. She’s inspired to ask new questions with the potential to shape an emerging field of medicine.

Leila’s story is the first in Making Possible, a video series about lives that have been touched by cell and gene therapy. Researchers share what it’s like to work toward …

/by

Leading performance in sustainability

People crossing the street in Cape Town

Novartis maitained its strong position in the Dow Jones Sustainability World Index with a percentile score of 91 (vs. 87 in 2019). We are proud of our industry-leading performance in the areas of social and environmental reporting, human capital …

/by

Results from real-world data and post-hoc analysis of Novartis Beovu® pivotal trials presented at AAO 2020

  • Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD1,2
     
  • Follows establishment of multi-disciplinary expert coalition and Novartis commitment to sharing data and findings with ophthalmology community
     
  • Despite existing therapies, significant unmet need still exists for wet AMD patients; data shows around half of patients have unresolved fluid, with a third requiring monthly injections3,4             

Basel, November 13, …

/by

New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender

  •  Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult patients and in three age categories1,2

  • Sustained LDL-C reduction with inclisiran was observed regardless of age or gender differences1,2 with two doses a year, after an initial dose and then again at three months; the overall …
/by

Study suggests there may be two stages of fatal lung disease in COVID-19

Cell samples from COVID19 lung tissue analysis

Translational immunologists from the Novartis Institutes for BioMedical …

/by

Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)

  • The Phase III trial investigating canakinumab plus standard of care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical ventilation, or its key secondary endpoint of reduced COVID-19 mortality, compared with SoC1

  • Ilaris® (canakinumab) remains an effective …
/by

Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study

  • Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx®  at Week 12  vs. placebo, with improvements as early as Week 11
     
  • ULTIMATE is the first ever Phase IIIb imaging study primarily looking at the time course of response to Cosentyx in biologic-naïve patients with active psoriatic arthritis (PsA) using Power Doppler ultrasonography (PDUS)1
     
  • PDUS is a sensitive technology, allowing detection and monitoring of early changes in synovitis and enthesitis1 …
/by